FrancophonIA/ELRC3.0 huggingface dataset:
English: Vidaza contains the active substance ‘azacitidine'.
Croatian: Vidaza sadržava djelatnu tvar azacitidin.
English: Eye disorders eye haemorrhage, conjunctival haemorrhage
Croatian: Poremećaji oka krvarenje u oku, krvarenje konjunktive
English: • if you have kidney disease.
Croatian: • ako imate bolest bubrega
English: bleeding into your skin (haematoma), rash, itching and changes in the skin colour.
Croatian: To uključuje oticanje, tvrdu kvržicu, modrice, krvarenje u kožu (hematom), osip, svrbež i promjene boje kože.
English: If the elapsed time in the refrigerator is greater than 22 hours, the suspension should be discarded appropriately and a new dose prepared.
Croatian: Ako je od pohrane u hladnjak proteklo više od 22 sata, suspenziju treba odgovarajuće zbrinuti i pripremiti novu dozu.
English: dose, mean exposure values (AUC and Cmax) from subjects with mild, moderate and severe renal impairment were increased by 11-21%, 15-27%, and 41-66%, respectively, compared to normal renal function subjects.
Croatian: U usporedbi s ispitanicima s normalnom funkcijom bubrega, nakon supkutane primjene jednokratne doze od 75 mg/m2, srednje vrijednosti izloženosti (AUC i Cmax) bile su povišene u ispitanika s blagim oštećenjem bubrega za 11-21 %, u onih s umjerenim oštećenjem za 15-27 %, a u bolesnika s teškim oštećenjem bubrega za 41-66 %.
English: • Feeling generally unwell.
Croatian: • opće loše osjećanje
English: Hepatobiliary disorders hepatic failure*, progressive hepatic coma
Croatian: Poremećaji jetre i žuči zatajenje jetre*, progresivna hepatička koma
English: SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN Keep out of the sight and reach of children.
Croatian: I DOHVATA DJECE Čuvati izvan pogleda i dohvata djece.
English: • Chest pain, being short of breath.
Croatian: • bol u prsnom košu, nedostatak zraka
English: If the bone marrow cellularity is > 50 %, no dose adjustments should be made.
Croatian: Prilagodba doze nije potrebna ako je celularnost koštane srži > 50 %.
English: Tell your doctor straight away if you become pregnant during treatment.
Croatian: Ako zatrudnite tijekom liječenja, odmah o tome obavijestite svog liječnika.
English: Grounds for the variation to the terms of the marketing authorisation(s)
Croatian: Razlozi za izmjenu uvjeta odobrenja za stavljanje lijeka u promet
English: 6.6 Special precautions for disposal and other handling
Croatian: 6.6 Posebne mjere za zbrinjavanje i druga rukovanja lijekom Upute za sigurno rukovanje
English: Skin and subcutaneous tissue adverse reactions
Croatian: Nuspojave na koži i potkožnome tkivu
English: Due to the potential serious adverse reactions in the nursing child, breast-feeding is contraindicated during azacitidine therapy.
Croatian: Dojenje je kontraindicirano tijekom liječenja azacitidinom zbog mogućih ozbiljnih nuspojava kod djeteta koje se doji.
English: If the elapsed time is longer than 30 minutes, the suspension should be discarded appropriately and a new dose prepared.
Croatian: Ako je proteklo više od 30 minuta, suspenziju treba odgovarajuće zbrinuti i pripremiti novu dozu.
English: MARKETING AUTHORISATION HOLDER Celgene Europe B.V.
Croatian: NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Celgene Europe B.V.
English: Advanced malignant hepatic tumours (see section 4.4).
Croatian: Uznapredovali maligni tumori jetre (vidjeti dio 4.4).
English: Log-Rank p = 0.0001 HR = 0.58 [95% CI: 0.43-0.77]
Croatian: Log-rang p = 0,0001
English: 5 How to store Vidaza Contents of the pack and other information
Croatian: Kako Vidaza izgleda i sadržaj pakiranja
English: Liver function tests, serum creatinine and serum bicarbonate should be determined prior to initiation of therapy and prior to each treatment cycle.
Croatian: Prije početka liječenja i prije svakog ciklusa liječenja treba odrediti pokazatelje jetrene funkcije, kreatinin u serumu i bikarbonate u serumu.
English: Recommendations for safe handling
Croatian: Upute za sigurno rukovanje
English: Unopened powder vial: 4 years
Croatian: Neotvorena bočica praška:
English: • Nosebleeds (epistaxis).
Croatian: • krvarenje iz nosa (epistaksa)
English: A patient experienced diarrhoea, nausea, and vomiting after receiving a single intravenous dose of approximately 290 mg/m2, almost 4 times the recommended starting dose.
Croatian: Nakon primjene jedne intravenske doze od približno 290 mg/m2, gotovo 4 puta veće od preporučene početne doze, kod bolesnika su se pojavili proljev, mučnina i povraćanje.
English: General disorders and administration site conditions pyrexia*, fatigue, asthenia, chest pain, injection site erythema, injection site pain, injection site reaction (unspecified)
Croatian: Opći poremećaji i reakcije na mjestu primjene pireksija*, umor, astenija, bol u prsištu, eritem na mjestu primjene, bol na mjestu primjene, reakcija na mjestu primjene (nespecifična)
English: Renal and urinary disorders renal failure*, haematuria, elevated serum creatinine renal tubular acidosis
Croatian: Poremećaji bubrega i mokraćnog sustava zatajenje bubrega*, hematurija, povišen serumski kreatinin bubrežna tubularna acidoza
English: Following Vidaza treatment, if the decrease in WBC or ANC or platelets from that prior to treatment is ≤ 50 %, or greater than 50 % but with an improvement in any cell line differentiation, the next cycle should not be delayed and no dose adjustment made.
Croatian: Sljedeći ciklus ne treba odgađati te dozu ne treba prilagođavati ako je nakon liječenja Vidazom smanjenje vrijednosti bijelih krvnih stanica ili apsolutnog broja neutrofila ili trombocita u odnosu na vrijednosti prije početka liječenja ≤ 50 % ili veće od 50 %, ali uz poboljšanje diferencijacije bilo koje stanične linije.
English: • Bleeding.
Croatian: • Krvarenje.
English: Reconstituted suspension For storage conditions after reconstitution of the medicinal product, see section 6.3.
Croatian: Uvjete čuvanja nakon rekonstitucije lijeka vidjeti u dijelu 6.3.
English: • A low blood platelet count (thrombocytopenia).
Croatian: • nizak broj trombocita (trombocitopenija).
English: In patients who were RBC transfusion dependent at baseline and became independent, the median duration of RBC transfusion independence was 13 months in the azacitidine group.
Croatian: Kod bolesnika koji su neovisni o transfuziji eritrocita, a bili su ovisni na početku liječenja, u skupini liječenoj azacitidinom medijan trajanja neovisnosti o transfuziji eritrocita bio je 13 mjeseci.
English: Common side effects (may affect up to 1 in 10 people)
Croatian: Česte nuspojave (mogu se javiti u do 1 na 10 osoba)
English: After reconstitution, each mL suspension contains 25 mg azacitidine.
Croatian: Nakon rekonstitucije svaki mL suspenzije sadrži 25 mg azacitidina.
English: Uncommon side effects (may affect up to 1 in 100 people)
Croatian: Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba)
English: If the Vidaza suspension is prepared using water for injections that has not been refrigerated, the suspension must be placed in the refrigerator (2 °C - 8 °C) immediately after it is prepared and kept refrigerated for up to a maximum of 8 hours.
Croatian: Ako je suspenzija Vidaze pripremljena s vodom za injekcije koja nije bila rashlađena, suspenziju se mora staviti u hladnjak (2 °C do 8 °C) odmah nakon pripreme te čuvati u hladnjaku najviše 8 sati.
English: • Tiredness (fatigue).
Croatian: • slabost (astenija)
English: If the Vidaza suspension is prepared using water for injections that has been stored in the refrigerator (2 °C - 8 °C), the suspension must be placed in the refrigerator (2 °C - 8 °C) immediately after it is prepared and kept refrigerated for up to a maximum of 22 hours.
Croatian: Ako je suspenzija Vidaze pripremljena rashlađenom vodom za injekcije (2 °C do 8 °C), suspenziju se mora staviti u hladnjak (2 °C do 8 °C) odmah nakon pripreme te držati u hladnjaku najviše 22 sata.
English: Complete blood counts should be performed prior to initiation of therapy and as needed to monitor response and toxicity, but at a minimum, prior to each treatment cycle.
Croatian: Da bi se nadzirao odgovor i toksičnost nužno je kompletnu krvnu sliku napraviti prije početka terapije i prema potrebi, ali barem prije svakog ciklusa liječenja.
English: • Liver failure.
Croatian: • zatajenje jetre
English: • Redness of your skin.
Croatian: • crvenilo kože
English: When reconstituting using refrigerated (2 °C to 8 °C) water for injections, the reconstituted suspension must be placed in a refrigerator (2 °C to 8 °C) immediately after reconstitution, and kept in a refrigerator for a maximum of 22 hours.
Croatian: Kada rekonstituirate lijek rashlađenom vodom za injekcije (2 °C do 8 °C), rekonstituiranu suspenziju treba staviti u hladnjak (2 °C do 8 °C) odmah nakon rekonstitucije te držati u hladnjaku maksimalno 22 sata.
English: Renal abnormalities, ranging from elevated serum creatinine and haematuria to renal tubular acidosis, renal failure and death were reported in patients treated with azacitidine (see section 4.4).
Croatian: Kod bolesnika liječenih azacitidinom, zabilježeni su bubrežni poremećaji u rasponu od povišenog serumskog kreatinina i hematurije do bubrežne tubularne acidoze, zatajenja bubrega i smrti (vidjeti dio 4.4).
English: After reconstitution with 4 mL of water for injections, the reconstituted suspension contains 25 mg/mL azacitidine.
Croatian: vode za injekcije, suspenzija sadrži 25 mg/mL azacitidina.
English: GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription
Croatian: European Organization for Research and Treatment of Cancer Core Quality of
English: When reconstituting using water for injections that has not been refrigerated, the reconstituted suspension must be placed in a refrigerator (2 °C to 8 °C) immediately after reconstitution, and kept in the refrigerator for a maximum of 8 hours.
Croatian: Kada rekonstituirate lijek vodom za injekcije koja nije bila rashlađena, rekonstituirana suspenzija mora se staviti u hladnjak (2 °C do 8 °C) odmah nakon rekonstitucije te čuvati u hladnjaku maksimalno 8 sati.
English: After reconstitution, each mL of suspension contains 25 mg azacitidine.
Croatian: Nakon rekonstitucije, 1 mL suspenzije sadrži 25 mg azacitidina.
English: • Rash.
Croatian: NSAID).
English: Platelets (x 109/l) *Recovery = counts ≥ nadir count + (0.5 x [baseline count - nadir count])
Croatian: Trombociti (x 109/L) *Oporavak = vrijednosti
English: muscle spasms, myalgia
Croatian: grčevi u mišićima, bol u mišićima
English: • Bruising.
Croatian: • omaglica
English: Do not use Vidaza
Croatian: Nemojte primjenjivati Vidazu:
English: • An infection in your urine.
Croatian: • infekcija mokraćnih puteva
English: Hepatic impairment
Croatian: Hematološke nuspojave
English: • Dizziness.
Croatian: • smetenost
English: Clinically significant inhibitory or inductive effects of azacitidine on cytochrome P450 enzymes are unlikely (see section 5.2).
Croatian: Klinički značajni inhibicijski ili indukcijski učinci azacitidina na enzime citokroma
English: - If you get any side effects talk to your doctor, pharmacist or nurse.
Croatian: - Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika, ljekarnika ili medicinsku sestru.
English: • Shivering (chills).
Croatian: • drhtanje (zimica)
English: • Muscle aches.
Croatian: • grčevi u mišićima
English: • Shaking.
Croatian: • osip
English: In some cases these reactions can become severe.
Croatian: U nekim slučajevima te reakcije mogu postati ozbiljne.
English: The injection is given into a vein over several minutes.
Croatian: Injekcija se ubrizgava u venu nekoliko minuta.
English: Further information can be found in the summary of the risk management plan.
Croatian: Dodatne informacije možete pronaći u sažetku plana upravljanja rizikom.
English: Response to treatment was considered good or excellent in about 90% of cases.
Croatian: Djelovanje lijeka smatralo se dobrim ili izvrsnim u oko 90 % slučajeva.
English: The full EPAR and risk management plan summary for Iblias can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Iblias dostupan je na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Iblias octocog alfa
Croatian: Iblias oktokog alfa
English: Comparable results were seen in patients who continued to take the medicine after completion of the initial study.
Croatian: Zapaženi su usporedivi rezultati u bolesnika koji su nastavili uzimati lijek nakon završetka početnog ispitivanja.
English: Other information about Iblias
Croatian: Ostale informacije o lijeku Iblias
English: It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use.
Croatian: Objašnjava kako je Agencija ocijenila lijek da bi preporučila njegovo odobrenje u EU-u te uvjete za njegovu primjenu.
English: Why is Iblias approved?
Croatian: Zašto je Iblias odobren?
English: What is Iblias and what is it used for?
Croatian: Što je Iblias i za što se koristi?
English: If they occur they may include: angioedema (swelling of tissues under the skin), burning and stinging at the injection site, chills, flushing, itchy rash over the whole body, headache, hives, hypotension (low blood pressure), lethargy, nausea (feeling sick), restlessness, tachycardia (rapid heartbeat), tightness of the chest, tingling, vomiting and wheezing.
Croatian: Ako se pojave, mogu uključivati: angioedem (oticanje tkiva ispod kože), žarenje i peckanje na mjestu ubrizgavanja, zimicu, navalu crvenila, osip praćen svrbežom po cijelom tijelu, glavobolju, koprivnjaču, hipotenziju (niski krvni tlak), letargiju, mučninu (osjećaj slabosti), nemir, tahikardiju (ubrzane otkucaje srca), stezanje u prsima, trnce, povraćanje i piskanje pri disanju.
English: This is a summary of the European public assessment report (EPAR) for Iblias.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Iblias.
English: What measures are being taken to ensure the safe and effective use of Iblias?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Iblias?
English: In 12 patients who required major surgery during the study, control of blood loss was also rated as good or excellent by the patients' doctors.
Croatian: U 12 bolesnika kod kojih je bio potreban veći kirurški zahvat tijekom ispitivanja, liječnici bolesnika također su kontrolu gubitka krvi ocijenili dobrom ili izvrsnom.
English: About 70% of the bleeding events that occurred were managed with a single injection of Iblias, and about another 15% responded to a second injection; the response was considered good or excellent in around 80% of cases.
Croatian: Oko 70 % epizoda krvarenja zaustavljeno je jednom injekcijom lijeka Iblias, a otprilike dodatnih 15 % reagiralo je na drugu injekciju; djelovanje lijeka u oko 80 %slučajeva smatralo se dobrim ili izvrsnim.
English: Hypersensitivity (allergic) reactions are uncommon with Iblias, affecting from 1 patient in 1,000 to less than 1 patient in 100.
Croatian: Reakcije preosjetljivosti (alergijske reakcije) nisu česte pri primjeni lijeka Iblias, mogu se javiti od 1 na 1 000 bolesnika do manje od 1 na 100 bolesnika.
English: It is not intended to provide practical advice on how to use Iblias.
Croatian: Svrha sažetka nije davati praktične savjete o korištenju lijeka Iblias.
English: It contains the active substance octocog alfa, which is the same as human factor VIII.
Croatian: Sadrži djelatnu tvar oktokog alfa, koja je jednaka ljudskom faktoru VIII.
English: Data from a supportive study also confirmed the benefits of preventative treatment with Iblias in reducing the number of bleeds.
Croatian: Podaci popratnog ispitivanja također su potvrdili koristi preventivnog liječenja lijekom Iblias u smanjenju broja krvarenja.
English: The active substance in Iblias, octocog alfa, works in the body in the same way as human factor VIII.
Croatian: Djelatna tvar lijeka Iblias, oktokog alfa, djeluje u tijelu na isti način kao ljudski faktor VIII.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Iblias's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Iblias nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: Patients may develop antibodies to hamster or mouse proteins; the medicine must not be used in patients who are hypersensitive (allergic) to octocog alfa or to hamster or mouse proteins.
Croatian: Bolesnici mogu razviti protutijela na proteine hrčka ili miša; lijek se ne smije primjenjivati u bolesnika preosjetljivih (alergičnih) na oktokog alfu ili proteine miša ili hrčka.
English: It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of bleeding.
Croatian: Zamjenjuje faktor VIII koji nedostaje i time potpomaže zgrušavanje krvi i omogućava privremenu kontrolu krvarenja.
English: A risk management plan has been developed to ensure that Iblias is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Iblias.
English: Regarding safety, the reported effects are in line with those expected for a factor VIII product.
Croatian: U pogledu sigurnosti primjene, zabilježene nuspojave u skladu su s očekivanim nuspojavama za lijek koji sadrži faktor VIII.
English: Iblias can only be obtained with a prescription and treatment should be under the supervision of a doctor who has experience in the treatment of haemophilia.
Croatian: Iblias se izdaje samo na liječnički recept te se liječenje mora provoditi pod nadzorom liječnika s iskustvom u liječenju hemofilije.
English: Iblias is a medicine used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of a clotting protein called factor VIII).
Croatian: Iblias je lijek koji se koristi za liječenje i sprečavanje krvarenja u bolesnika s hemofilijom A (nasljednim poremećajem krvarenja prouzročenim manjkom proteina za zgrušavanje pod nazivom faktor VIII).
English: Iblias has been shown to be effective in both preventing and treating bleeds, including managing blood loss during surgery, and can be used in all age groups.
Croatian: Lijek Iblias pokazao se učinkovitim u sprečavanju i liječenju krvarenja, uključujući upravljanje gubitkom krvi tijekom kirurškog zahvata te ga mogu koristiti sve dobne skupine.
English: The effectiveness of Iblias in preventing and treating bleeding has been shown in a main study involving 62 patients aged 12 years or older with severe haemophilia A who were previously treated with other factor VIII products.
Croatian: Djelotvornost lijeka Iblias u sprečavanju i liječenju krvarenja dokazana je u glavnom ispitivanju koje je uključivalo 62 bolesnika u dobi od 12 ili više godina s teškom hemofilijom A, koji su prethodno liječeni drugim lijekovima koji sadrže faktor VIII.
English: What are the risks associated with Iblias?
Croatian: Koji su rizici povezani s lijekom Iblias?
English: Iblias is available as a powder and solvent used to make a solution for injection.
Croatian: Iblias je dostupan kao prašak i otapalo koji se zajedno miješaju kako bi se dobila otopina za injekciju.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Iblias, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetak opisa svojstava lijeka kao i u uputi o lijeku za lijek Iblias nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: The dose and frequency of the injections depend on whether Iblias is used to treat or prevent bleeding, the severity of the patient's factor VIII deficiency, the extent and location of the bleeding and the patient's condition and bodyweight.
Croatian: Doza i učestalost ubrizgavanja injekcijom ovise o tome koristi li se Iblias za liječenje ili sprečavanje krvarenja te o težini manjka faktora VIII u bolesnika, količini i mjestu krvarenja te stanju i težini bolesnika.
English: A second study involved 51 children under 12 years of age previously treated with other factor VIII products, who also had 3.8 bleeds per year on average during treatment with Iblias (mostly related to injuries).
Croatian: U drugo ispitivanje bilo je uključeno 51 dijete u dobi ispod 12 godina prethodno liječeno drugim lijekovima koji sadrže faktor VIII, a u kojih je tijekom liječenja lijekom Iblias došlo do krvarenja u prosjeku 3,8 puta godišnje (uglavnom zbog ozljeda).
English: For further information, see the summary of product characteristics (also part of the EPAR).
Croatian: Za dodatne informacije vidjeti sažetak opisa svojstava lijeka (također dio EPAR-a).
English: There is also a risk with factor VIII medicines that some patients will develop inhibitors (antibodies) against factor VIII, causing the medicine to stop working and resulting in a loss of bleeding control.
Croatian: Kod lijekova koji sadrže faktor VIII također postoji opasnost od razvoja inhibitora (protutijela) faktora VIII u nekih bolesnika, koji zaustavljaju djelovanje lijeka i dovode do gubitka kontrole nad krvarenjem.
English: In addition, the company that markets Iblias will complete studies to investigate the safety and efficacy of the medicine in patients who have not previously been treated with other factor VIII products, and to provide further evidence of the safety and efficacy of long-term treatment with Iblias in children.
Croatian: Nadalje, tvrtka koja lijek Iblias stavlja u promet dovršit će ispitivanja kako bi se istražila sigurnost i djelotvornost lijeka u bolesnika koji nisu prethodno liječeni drugim lijekovima koji sadrže faktor VIII te kako bi se omogućili dodatni podaci o sigurnosti i djelotvornosti dugotrajnog liječenja lijekom Iblias u djece.
English: For more information about treatment with Iblias, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Iblias pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily and may have problems such as bleeding into the joints, muscles and internal organs.
Croatian: Bolesnici s hemofilijom A nemaju dostatne razine faktora VIII, proteina potrebnog za normalno zgrušavanje krvi, pa stoga lako krvare te mogu imati probleme poput krvarenja u zglobovima,
English: Further evidence of effectiveness and safety in patients previously untreated with factor VIII medicines, and further data on long-term use in children should be provided by ongoing studies.
Croatian: Daljnjim ispitivanjima trebali bi se omogućiti dodatni podaci o djelotvornosti i sigurnosti u bolesnika koji nisu bili prethodno liječeni lijekovima koji sadrže faktor VIII, kao i dodatni podaci o dugoročnoj primjeni u djece.
English: How is Iblias used?
Croatian: Kako se Iblias koristi?
English: How does Iblias work?
Croatian: Kako djeluje Iblias?
English: What benefits of Iblias have been shown in studies?
Croatian: Koje su koristi lijeka Iblias utvrđene u ispitivanjima?
English: For practical information about using Iblias, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka Iblias pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
English: This compared with an average of 6.9 bleeds per year before Iblias treatment.
Croatian: Izračunato je da je u prosjeku do pojave krvarenja tijekom liječenja lijekom Iblias došlo 3,8 puta godišnje (uglavnom u zglobovima), u usporedbi s prosječno 6,9 krvarenja godišnje prije liječenja lijekom Iblias.